The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) – Chris Sweeney & Mary-Ellen Taplin

Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy…

Read the full article here

Source: UroToday

Categories: Urology

Tags: mHSPC

Tweets with this article

UroToday.com

#mHSPC @ChrisSweens1 and Mary-Ellen Taplin, MD @DanaFarber discuss their approaches for treating patients with metastatic hormone sensitive prostate cancer and various trials in this setting with @CaPsurvivorship @NUFeinbergMed on UroToday. https://t.co/dQmFzajSu3 #ProstateCancer https://t.co/30bd3QeCaM

A Free Method for Patient-Specific 3D-VR Anatomical Modeling for Presurgical Planning Using DICOM Images and Open-Source Software – Beyond the Abstract

Patient-Specific 3D-VR Anatomical Modeling, DICOM Images, Patient-Specific 3D-VR Anatomical Modeling for Presurgical Planning Using DICOM Images and Open-Source Software, PSMA PET/CT, 99mTc-PSMA-I&S, salvage pelvic lymph…

UroToday.com May 22, 2025

Evolution of Chemohormonal Therapy for Metastatic Prostate Cancer – Pedro Barata

Zachary Klaassen speaks with Pedro Barata about chemohormonal therapy and treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Barata traces the evolution from 2015 when…

UroToday.com May 22, 2025

PRIMARY Score and Where it Plays a Role in Prostate Cancer Diagnosis “Presentation” – Michael Hofman

At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman presents the PRIMARY score for PSMA PET in prostate cancer diagnosis. He explains how PSMA PET complements…

UroToday.com May 20, 2025

Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis – Ken Herrmann

Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann…

UroToday.com May 20, 2025

Can PSMA-Targeted Prostate Biopsy Detect Cancer When MRI-Guided Biopsy is Negative? “Presentation” – Wayne Brisbane

At the 2025 UCSF-UCLA PSMA Conference, Wayne Brisbane presents a phase I trial examining PSMA-targeted prostate biopsy following negative/discordant MRI biopsies. Among 39 patients with…

UroToday.com May 19, 2025

PRECISION Data Platform Reveals mCRPC Treatment Outcomes in Urology Practices – Neal Shore

Zachary Klaassen interviews Neal Shore about real-world treatment patterns for mCRPC patients in community urology centers using the PRECISION database. Dr. Shore analyzes data from…

UroToday.com May 18, 2025

Risk Stratification for Active Surveillance in Low and Intermediate-Risk Bladder Cancer – Marco Moschini

Ashish Kamat speaks with Marco Moschini about expanding active surveillance criteria for recurrent low-grade bladder cancer. Dr. Moschini presents his single-center retrospective study from San…

UroToday.com May 17, 2025

Initial Linguistic and Cultural Validation of the Satisfaction Survey for Inflatable Penile Implant (SSIPI) in Spanish – Beyond the Abstract

erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.

UroToday.com May 13, 2025

Optimizing Treatment in Metastatic Hormone-Sensitive Prostate Cancer: A Case Study Analysis – Alicia Morgans

Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alicia…

UroToday.com May 11, 2025

Landscape of Approved and Upcoming PSMA Imaging Agents “Presentation” – Amir Iravani

At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar…

UroToday.com May 11, 2025

Related Articles